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Background. Although acquired immune deﬁciency syndrome-associated morbidity has diminished due to ex-
cellent viral control, multimorbidity may be increasing among human immunodeﬁciency virus (HIV)-infected per-
sons compared with the general population.
Methods. We assessed the prevalence of comorbidities and multimorbidity in participants of the Swiss HIV Co-
hort Study (SHCS) compared with the population-based CoLaus study and the primary care-based FIRE (Family
Medicine ICPC-Research using Electronic Medical Records) records. The incidence of the respective endpoints
were assessed among SHCS and CoLaus participants. Poisson regression models were adjusted for age, sex, body
mass index, and smoking.
Results. Overall, 74 291 participants contributed data to prevalence analyses (3230 HIV-infected; 71 061 controls).
In CoLaus, FIRE, and SHCS, multimorbidity was present among 26%, 13%, and 27% of participants. Compared with
nonsmoking individuals from CoLaus, the incidence of cardiovascular disease was elevated among smoking individuals
but independent of HIV status (HIV-negative smoking: incidence rate ratio [IRR] = 1.7, 95% conﬁdence interval
[CI] = 1.2–2.5; HIV-positive smoking: IRR = 1.7, 95% CI = 1.1–2.6; HIV-positive nonsmoking: IRR = 0.79, 95%
CI = 0.44–1.4). Compared with nonsmoking HIV-negative persons, multivariable Poisson regression identiﬁed associ-
ations of HIV infection with hypertension (nonsmoking: IRR = 1.9, 95% CI = 1.5–2.4; smoking: IRR = 2.0, 95%
CI = 1.6–2.4), kidney (nonsmoking: IRR = 2.7, 95% CI = 1.9–3.8; smoking: IRR = 2.6, 95% CI = 1.9–3.6), and liver dis-
ease (nonsmoking: IRR = 1.8, 95% CI = 1.4–2.4; smoking: IRR = 1.7, 95% CI = 1.4–2.2). No evidence was found for an
association of HIV-infection or smoking with diabetes mellitus.
Conclusions. Multimorbidity is more prevalent and incident in HIV-positive compared with HIV-negative indi-
viduals. Smoking, but not HIV status, has a strong impact on cardiovascular risk and multimorbidity.
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Combination antiretroviral treatment has signiﬁcantly improved
life expectancy of human immunodeﬁciency virus (HIV)-
positive individuals [1]. With close to normal life expectancy,
HIV-positive persons may face sequential or concurrent comor-
bidities leading to increased mortality and multimorbidity [2, 3].
Multimorbidity, often deﬁned as co-occurrence of more than 2
conditions [4], is known to negatively affect health outcomes in-
cluding a decline in functional status, increased disability, and
lower quality of life. Another consequence of multimorbidity is
an increased number of medications (polypharmacy) [5].
An important focus of current clinical HIV research is to
identify whether HIV-positive individuals with suppressed
viral replication develop earlier or different comorbidities com-
pared with HIV-negative persons. Previous comparisons have
shown conﬂicting results regarding cardiovascular disease
(CVD), stroke, hypertension, diabetes mellitus, psychiatric
disorders, and diseases of bone, lung, kidney, and liver [6–21].
Possible reasons for the discrepancies are differences in the selec-
tion of the HIV-negative controls, either nested within a popula-
tion with comparable life styles [7–10, 12, 13, 15, 17, 18, 22] or
based on administrative data from the same geographic area or
hospital [11, 14, 16, 19–21].Other reasons include the limitations
of adjusting for important confounders such as smoking or body
mass index (BMI) [8, 9, 11, 13, 14, 16, 20].
The aim of the present study is to compare the prevalence
and incidence of different comorbidities and multimorbidity
in participants of the Swiss HIV Cohort Study (SHCS) with 2
HIV-negative populations in Switzerland.
METHODS
Data Sources Included in the Study
The SHCS [23] was established in 1988 and is an open cohort
study with continued enrollment of cumulatively approximately
18 000 HIV-infected persons, aged ≥16 years. Demographic,
psychosocial, clinical, laboratory, and treatment information is
systematically collected every 6 months. Information on cardio-
vascular endpoints, diabetes mellitus, and renal and liver dis-
ease is ascertained and centrally adjudicated within the Data
Collection on Adverse Events of Anti-HIV Drugs (D:A:D)
study [24].
Cohorte Lausannoise (CoLaus) [25] is a population-based
study that investigates the clinical, biological, and genetic deter-
minants of CVD. Cohorte Lausannoise performs endpoint ad-
judication of cardiovascular events, diabetes, and psychiatric
disorders. Moreover, they have access to the electronic patient
records of the hospitals and are linked to the death registry. Par-
ticipants aged 35–75 years old were recruited in 2003 among 19
830 randomly selected inhabitants of Lausanne, Switzerland.
The baseline characterization of 6182 participants was per-
formed during 2003–2006, and a ﬁrst follow-up visit on more
than 5000 of these individuals was done during 2009–2013.
Family Medicine ICPC-Research using Electronic Medical
Records (FIRE) [26] is a Swiss primary care project that has en-
rolled approximately 150 000 patients from 75 general practi-
tioners since 2009 and uses medical data retrieved from
electronic patient records. Laboratory results and demographi-
cal and clinical information are collected at routine visits. Mor-
bidity is classiﬁed according to the International Classiﬁcation
of Primary Care (ICPC-2) codes [27], and information on the
type of prescribed medications is based on the Anatomical
Therapeutic Chemical classiﬁcation System (ATC) [28]. The
FIRE analyzed prevalence estimates of chronic conditions in a
recent study and found an age- and gender-speciﬁc distribution
comparable with other primary care data sources in Switzerland
[29]. Information on smoking and alcohol use has not yet been
collected in FIRE, and there is only limited information on liver
disease and weight available. There is an inherent selection bias
in BMI measurements in FIRE because the weight was more
likely assessed in case of overweight or obese participants.
The FIRE data could not be used for incidence analysis due
to limited accumulated follow-up time.
Study Participants
Individuals from SHCS and CoLaus were eligible if they were
Caucasian, noninjecting drug users (non-IDUs), ≥35 years
old at a study visit 2003–2006 (baseline), and if they had at
least 1 follow-up visit 5–6 years later. The FIRE patients were
eligible if they were Caucasian, non-IDUs, ≥40 years old, and
if they had ≥1 visit between January 1, 2009 and December
31, 2011. Thus, all participants were at least 40 years old in
2009–2011 and contributed to prevalence analyses. For the con-
ceptual design, refer to Supplementary Figure 1. All cohorts
were approved by the local Ethics Committees.
Deﬁnitions
Clinical events were validated according to the standards of
each cohort. We collected information on the following clinical
events: CVDs (myocardial infarction, coronary heart disease
with/without angina, heart failure and coronary heart disease,
coronary artery bypass graft, and coronary angioplasty/stent-
ing); stroke; diabetes mellitus (diabetes mellitus insulin-depen-
dent/insulin-resistant and use of oral antidiabetics or insulin
[ATCA10*, Pharmaceutical Cost Group (PCG): A10]); hyper-
tension (measured diastolic or a systolic blood pressure >90/
>160 mm Hg, or use of antihypertensive medications [ATC
C0*; PCG: C02, C03A, C03EA01 C07, C08, C09A, C09B]); kid-
ney insufﬁciency (glomerular ﬁltration rate <60 mL/min, Mod-
iﬁcation of Diet in Renal Disease formula) [30]; and liver event
(alanine transaminase [ALT] >50 U/L for males/35 U/L for fe-
males). We used the term “comorbidities” throughout the man-
uscript. Multimorbidity was termed as the co-occurrence of at
least 2 of the above-mentioned conditions (ie, ≥2 comorbidi-
ties). By deﬁnition, HIV infection was not considered as a
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comorbid condition. In CoLaus and SHCS, comedications were
recorded according to the ATC [28], and FIRE was applied to a
PCG model [27]. We recorded the use of antihypertensives and
antidiabetics. A table indicating the deﬁnitions of each clinical
event is available in the appendix (Supplementary Table 1).
Patients were stratiﬁed by the following BMI categories: un-
derweight, <18.5 kg/m2; normal, 18.5–24.9 kg/m2; overweight,
25–29.9 kg/m2); and obese, ≥30 kg/m2 [31]. We distinguished
2 smoking categories: ever/current smokers and nonsmokers.
Age was stratiﬁed into <50, 50–65, and 65+ years. Information
on HIV infection included years since ﬁrst HIV diagnosis and
cumulative exposure to drug classes (protease inhibitor [PI],
nonnucleoside reverse transcriptase inhibitor [NNRTI]-based
antiretroviral therapy [ART] combinations).
Statistical Analysis
Differences between cohorts were analyzed by χ2 tests for cate-
gorical variables and Kruskal-Wallis tests for continuous vari-
ables. We calculated the cumulative prevalence of endpoints
for CoLaus, FIRE, and SHCS until end of 2011. Logistic regres-
sion analyses were adjusted for age groups and sex among all
cohorts, and in SHCS and CoLaus models were further adjusted
for smoking and BMI.
We calculated incidence rates of endpoints as the number of
new endpoints since the ﬁrst visit in 2003–2006 divided by the
number of person-years of follow up. The time at risk for pa-
tients without an event was calculated as time between the base-
line visit and the follow-up visit. In case of an event, we used the
time from baseline until the date of the event. Because precise
dates of diabetes mellitus, hypertension, kidney disease, and
liver disease were not available in CoLaus, we used the midpoint
between the baseline and follow-up visit for these events. To
check whether this approximation was valid, we compared Co-
Laus estimates for cardiovascular events and stroke using the
available dates with the estimates using the midpoint of baseline
and follow-up visit. The ﬁndings were unchanged (data not
shown). Comparisons of incidence across CoLaus and SHCS
were done with Poisson regression adjusted for sex, age groups,
BMI groups, and smoking as an interaction term. To rule out
important effect attenuation by using stratiﬁed age and BMI
values, we performed sensitivity analyses using continuous
age and BMI measurements. We excluded IDUs and therefore
we assumed hepatitis C virus (HCV) would not contribute to
the endpoint liver disease. To check this, we performed a sensi-
tivity analysis and excluded HCV-infected individuals in other
HIV transmission groups than IDUs. We used Stata/SE (version
13.1; StataCorp, College Station, TX) for analyses.
RESULTS
Patients Characteristics
Characteristics of the participants are shown in Table 1. Com-
pared with the SHCS, participants from FIRE and CoLaus were
older, more frequently female, and had a higher BMI; previous
or current smoking was more prevalent in the SHCS than in
CoLaus.
The median duration of HIV infection in the SHCS was 14
years (interquartile range [IQR], 9.5–19). Median exposure
times to PI or NNRTI-based ART regimens were 4.5 years
(IQR, 0.99–8.8) and 2.6 years (IQR, 0.0–6.6), respectively.
Nadir CD4 cell count was 172 (70–259), latest CD4 count
was 572 (IQR, 420–754) cells/µL, and 880 (27%) of SHCS
Table 1. Characteristics of 74 291 Participants, Stratiﬁed by Cohort
Variables
Cohorts
CoLaus 2009–2011 FIREa 2009–2011 SHCS 2009–2011 P Valueb
Participants, n (%) 4569 (6) 66 492 (90) 3230 (4) –
Female, n (%) 2450 (54) 34 968 (53) 607 (19) <.001
Age, median years (IQR) 57 (49–67) 59 (49–72) 50 (45–58) <.001
Smoking, ever, n (%) 2725 (60) – 2166 (68) <.001
Smoking, current, n (%) 989 (22) – 1179 (37) <.001
BMI, kg/m2, median (IQR) 26 (23–29) 27 (24–30) 24 (22–26) <.001
BMI groups, n (%) <.001
underweight 71 (2) 168 (0) 153 (5)
normal 1929 (42) 3853 (6) 1879 (58)
overweight 1778 (39) 4945 (7) 969 (30)
obese 791 (17) 3384 (5) 2249 (7)
missing 0 (0) 54 142 (81) 0 (0)
Abbreviations: BMI, body mass index; IQR, interquartile range; SHCS, Swiss HIV Cohort Study; CoLaus, Cohorte Lausannoise; FIRE, Family Medicine ICPC-
Research using Electronic Medical Records.
a Information on smoking is missing and BMI is available only for 12 350 FIRE participants.
b P values from 2 × 3 χ2 tests (categorical variables) and Kruskal-Wallis tests (continuous variables).
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participants had a prior acquired immune deﬁciency syndrome
(AIDS)-deﬁning event. The percentage of SHCS participants on
ARTwith an event was between 96.4% and 100%, depending on
the respective endpoint. Median CD4 cells among those with or
without (1) CVD and (2) stroke, liver or kidney disease, diabe-
tes, and hypertension were as follows, respectively: CVD, 459.5
(IQR, 340–602) and 508 (IQR, 370–699) cells/L; stroke, 443
(IQR, 270–590) and 522.5 (IQR, 386–798) cells/L; liver disease,
570 (IQR, 430–763) and 571 (IQR, 424.5–751) cells/L; kidney
disease, 511 (IQR, 397–695) and 572 (IQR, 430–758) cells/L; di-
abetes, 560 (IQR, 384–850) and 510 (IQR, 373–701) cells/L; and
hypertension, 544 (IQR, 392–731) and 549 (IQR, 404–735)
cells/L.
Prevalence Analyses
A total of 4569 CoLaus participants, 66 492 FIRE participants,
and 3230 SHCS participants contributed to the prevalence anal-
yses of different comorbidities. Multimorbidity was present in
26%, 13%, and 27% for CoLaus, FIRE, and SHCS, respectively.
In unadjusted logistic regression analysis, most comorbidities
were less prevalent in FIRE participants compared with CoLaus
and SHCS. When comparing the SHCS with CoLaus, the unad-
justed prevalence of CVD (odds ratio [OR] = 1.5, 95% conﬁdence
interval (CI) = 1.2–1.9) and liver disease (OR = 1.2, 95% CI = 1.1–
1.4) were increased, and diabetes mellitus (OR = 0.60, 95%
CI = 0.51–0.71) and kidney disease (OR = 0.76, 95% CI = 0.65–
0.88) were less prevalent among HIV-infected individuals. Ad-
justed models, only SHCS and CoLaus showed associations of
HIV with all comorbidities (CVD: OR = 2.1, 95% CI = 1.6–2.7;
stroke: OR = 2.3, 95% CI = 1.4–3.6; hypertension: OR = 1.4, 95%
CI = 0.62–0.77; kidney disease: OR = 1.6, 95% CI = 1.5–2.2; liver
disease: OR = 1.3, 95% CI = 1.5–2.0) except for diabetes mellitus
resulting in an adjusted OR of 1.7 (95% CI = 1.5–2.0) for multi-
morbidity. Table 2 shows unadjusted and adjusted results of logis-
tic regression with smoking as an interaction term. We found
evidence of an increased prevalence of CVD among smoking in-
dividuals irrespective of HIV status. Hypertension, kidney disease,
and liver disease were associated with HIV-infection but not with
smoking. For stroke, HIV and smoking had an additive effect.
Diabetes mellitus was associated with HIV-negative, smoking
individuals (Figure 1 and Supplementary Table 2).
Incidence Analyses
The 3230 SHCS and 4569 CoLaus participants contributed 43
313 person-years of follow up and an average follow up of 5.5
years per person. Compared with CoLaus, we observed higher
adjusted incidences of hypertension (incidence rate ratio
[IRR] = 1.8, 95% CI = 1.6–2.1), kidney disease (IRR = 1.8, 95%
CI = 1.6–2.1), and liver disease (IRR = 1.8, 95% = CI 1.6–2.1)
and a lower rate of diabetes mellitus (IRR = 0.72, 95% = CI
0.56–0.93) among SHCS participants. Table 3 and Supplemen-
tary Table 3 show the incidence rates and unadjusted and
adjusted incidence rate ratios of different comorbidities with
smoking as an interaction term. Adjusted analyses showed a dif-
ferent effect of smoking status for the respective comorbidities.
As shown in Figure 2, incident CVD and—to a lesser extent—
stroke were not increased among HIV-positive patients when
stratiﬁed by smoking. Hypertension and kidney and liver dis-
ease appeared more frequently among HIV-positive individuals
irrespective of smoking. Incidences of all comorbidities except
liver disease increased with age in each cohort. Results from
sensitivity analyses using continuous age and BMI values in-
stead of stratiﬁed variables were similar. The association of
HIV with the liver disease remained unchanged after excluding
HCV-infected individuals in the SHCS.
Incident multimorbidity was found in 1147 of 7799 (15%)
subjects. Compared with nonsmoking CoLaus participants, in-
cident multimorbidity was increased among nonsmoking and
smoking SHCS participants with IRR of 1.7 (95% CI = 1.4–
2.1) and 1.9 (95% CI = 1.5–237), respectively. Eighty percent
of multimorbid SHCS participants had 2 comorbidities, 19%
had 3 comorbidities, and 1.3% had 4 or more comorbidities.
Among SHCS participants, the most frequent combinations
were as follows: hypertension plus liver disease (29%), hyper-
tension plus diabetes (23%), or hypertension plus kidney dis-
ease (14%). The most frequent combinations among CoLaus
participants were as follows: hypertension plus diabetes mellius
(41%), hypertension plus liver disease (14%), and hypertension
plus kidney disease (12%).
DISCUSSION
In this comparative analysis of an HIV cohort (SHCS) with a
population-based (CoLaus) and a primary care-based study
(FIRE) in Switzerland, we found evidence for an increased prev-
alence and incidence of comorbidity and multimorbidity
among Swiss HIV-positive persons. The prevalence and inci-
dence of CVD was similar among HIV-positive and -negative
patients when stratiﬁed by smoking status. There was an excess
prevalence and incidence among HIV-positive individuals for
hypertension, kidney, and liver disease that was independent
of smoking. For incident stroke, HIV and smoking appeared
to have an additive effect. We did not ﬁnd evidence for an in-
creased prevalence or incidence of diabetes mellitus associated
with HIV infection or smoking.
The effect of HIV on CVD and stroke disappears after adjust-
ment for BMI and smoking. The comparison of our ﬁndings
with published literature is difﬁcult because either combined
cardiovascular endpoints, acute myocardial infarction only, or
separated individual components of CVD were reported.
Most importantly, adjustment for smoking and BMI is lacking
in many studies [8, 9, 14, 16, 20].However, our results are in line
with recent studies. Rasmussen et al [21] investigated HIV-
infected individuals with incident mycocardial infarction from
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Table 2. Numbers of Prevalent Comorbidities, Stratiﬁed by Cohorta
Cohort
All Events,
n (%)
Hypertension,
n (%)
Liver Disease,
n (%)
Diabetes Mellitus,
n (%)
Kidney Disease,
n (%)
Cardiovasc. Disease,
n (%)
Stroke,
n (%)
Multimorbidity,
n (%)
CoLaus nonsmoking 1844 (100) 842 (46) 298 (16) 167 (9) 207 (11) 38 (2) 17 (1) 373 (20)
CoLaus smoking 2725 (100) 1296 (48) 451 (17) 358 (13) 273 (10) 114 (4) 34 (1) 647 (24)
FIRE 66 492 (100) 22 206 (33) −b 4500 (7) 509 (1) 2407 (4) 699 (1) 5661 (9)b
SHCS nonsmoking 1064 (100) 515 (48) 212 (20) 89 (8) 102 (10) 33 (3) 14 (1) 233 (22)
SHCS smoking 2166 (100) 941 (43) 405 (19) 146 (7) 161 (7) 126 (6) 37 (2) 448 (21)
Unadjusted logistic regression OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
CoLaus nonsmoking 1 1 1 1 1 1 1
CoLaus smoking 1.1 (0.96–1.2) 1.0 (0.88–1.2) 1.5 (1.2–1.8) 0.88 (0.73–1.1) 2.1 (1.4–3.0) 1.4 (0.76–2.4) 1.2 (1.1–1.4)
FIRE 0.60 (0.54–0.65) – 0.73 (0.62–0.86) 0.06 (0.05–0.07) 1.8 (1.3–2.5) 1.1 (0.70–1.9) 0.59 (0.51–0.67)b
SHCS nonsmoking 1.1 (0.96–1.3) 1.3 (1.1–1.6) 0.92 (0.70–1.2) 0.84 (0.65–1.1) 1.5 (0.95–2.4) 1.4 (0.70–2.9) 1.1 (0.92–1.3)
SHCS smoking 0.91 (0.81–1.0) 1.2 (1.0–1.4) 0.73 (0.58–0.91) 0.64 (0.51–0.79) 2.9 (2.0–4.2) 1.9 (1.0–3.3) 1.0 (0.88–1.2)
Adjusted logistic regressionc OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
CoLaus nonsmoking 1 1 1 1 1 1 1
CoLaus smoking 1.0 (0.89–1.1) 0.97 (0.82–1.1) 1.3 (1.1–1.6) 0.96 (0.79–1.2) 1.8 (1.2–2.7) 1.3 (0.73–2.4) 1.1 (0.98–1.3)
FIREc – – – – – – –
SHCS nonsmoking 1.4 (1.2–1.7) 1.3 (1.0–1.6) 1.0 (0.78–1.4) 1.6 (1.2–2.2) 1.7 (1.0–2.8) 1.9 (0.91–4.1) 1.5 (1.2–1.8)
SHCS smoking 1.4 (1.2–1.6) 1.2 (1.0–1.5) 1.0 (0.79–1.3) 1.5 (1.1–1.9) 4.1 (2.7–6.2) 3.2 (1.7–6.2) 1.7 (1.4–2.0)
Female sex 0.69 (0.62–0.77) 0.85 (0.74–0.97) 0.42 (0.35–0.51) 1.8 (1.5–2.2) 0.45 (0.33–0.60) 0.75 (0.47–1.2) 0.69 (0.61–0.79)
Age group, 50–65 yd 2.1 (1.9–2.3) 1.0 (0.90–1.2) 2.6 (2.0–3.2) 2.9 (2.2–3.7) 4.6 (3.0–7.0) 3.5 (1.6–7.3) 3.4 (2.7–4.2)
Age group, +65yd 5.2 (4.5–5.9) 0.61 (0.51–0.73) 5.5 (4.3–7.0) 9.0 (7.0–12) 15 (1.2–1.9) 16 (7.9–34) 12 (10–16)
Normal weighte 1.4 (1.0–1.9) 0.83 (0.56–1.2) 1.2 (0.57–2.7) 0.60 (0.39–0.91) 0.94 (0.46–1.9) 1.7 (0.40–7.1) 0.84 (0.53–1.3)
Overweighte 2.7 (2.0–3.7) 1.5 (1.0–2.2) 2.9 (1.3–6.2) 0.78 (0.51–1.2) 1.1 (0.53–2.2) 1.5 (0.34–6.3) 1.5 (0.94–2.4)
Obesee 6.2 (4.4–8.6) 2.9 (1.9–4.3) 8.3 (3.8–18) 0.85 (0.54–1.3) 1.6 (0.74–3.3) 1.8 (0.39–8.0) 3.8 (2.4–6.0)
Abbreviations: BMI, body mass index; Cardiovasc., cardiovascular; CI, confidence interval; CoLaus, Cohorte Lausannoise; FIRE, Family Medicine ICPC-Research using Electronic Medical Records; OR, odds ratio; SHCS,
Swiss HIV Cohort Study; y, year old.
a Unadjusted and adjusted results of logistic regression analyses with smoking as an interaction term. Adjusted logistic regression models were adjusted for all variables listed.
b There is only limited information on liver endpoints available in FIRE. Therefore, we do not provide the liver endpoint for FIRE, and the multimorbidity endpoint for FIRE includes no liver disease.
c Reference group: nonsmoking participants from CoLaus. FIRE was omitted in multivariable models due to missing information on smoking and limited avilability of BMI values.
d Reference group: 35- to 49-year-old participants.
e Reference group: underweight participants.
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the Danish HIV Cohort Study and compared them with popu-
lation controls matched on age and gender. They found higher
rates of mycocardial infarction in smoking individuals irrespec-
tive of HIV status (HIV+ nonsmoking: IRR = 1.01, 95%
CI = 0.41–2.54; HIV+ previous and current smokers:
IRR = 1.78, 95% CI = 0.75–4.24); and adjusted IRR = 2.83,
95% CI, = 1.71–4.70). The Veterans aging Cohort primarily in-
vestigated the age at, and the risk of incident diagnosis of, myo-
cardial infarction, kidney disease, and non-AIDS-deﬁning
cancer. Althoff et al [22] did not ﬁnd a difference in the age
at diagnosis of these age-associated diseases compared with
HIV-negative individuals, again challenging the concept of pre-
mature aging among HIV patients. Our results of increased
risks of kidney and liver disease but not of diabetes mellitus
among HIV-positive individuals are congruent with published
studies [9, 12, 15–18, 20]. Findings regarding an association of
hypertension with HIV have been inconsistent: although the
AGEhIV study in the Netherlands [17] and our study found
strong associations of HIV with hypertension, other studies
reported no [15, 20] or even negative associations of HIV [9]
with hypertension.
Finding adequate HIV-negative control groups to identify the
independent effect of HIV on age-related comorbidities is chal-
lenging. The approaches differ from study to study and may
contribute to the heterogeneity of observed results. Some stud-
ies have included HIV-negative persons from the same health-
care plan [9, 12, 13], same clinics [8, 17], focused on speciﬁc risk
groups [15], used individual administrative data from the region
[11, 16, 18, 20, 21], or used published data from the general pop-
ulation [14]. In our study, CoLaus, a well documented prospec-
tive HIV-negative cohort with validated endpoints, contributed
to prevalence and incidence analyses, and FIRE, a large patient
registry from private physicians, contributed to prevalence anal-
yses. Because participants in CoLaus likely are a selection of
motivated health-seeking persons, the absence of an increased
cardiovascular risk in our study, when comparing SHCS and
CoLaus participants, is noteworthy. The FIRE participants, on
the other hand, are observed by general practicioners, and thus
they may be expected to be healthier, which may explain the
lower prevalence of multimorbidity in FIRE.
Several limitations should be noted. We were unable to in-
clude some important conditions such as cancer, osteoporosis,
and pulmonary disease. There might be important lifestyle and
socioeconomic demographics differences among comparator
groups. Hence, we excluded IDUs because of signiﬁcant imbal-
ances between the cohorts and the resulting confounding. Un-
derreporting of a history of IDU in SHCS participants with
other known risk factors for HIV is possible. Alanine transam-
inase elevations may be transient in nature, and hence it might
not be appropriate to take ALT elevations as a proxy for “liver
disease”. However, recent literature indicates that high ALT lev-
els are associated with a higher risk of liver-related mortality
and diabetes [32]. As a condition for incidence analyses, we re-
quired that participants must have survived at least 6 years.
There is no formal record linkage with other hospitals, and
hence we cannot exclude that information on comorbidities is
not complete. Three hundred of 3998 (7.5%) SHCS participants
and 184 of 6122 (3%) CoLaus participants died in 2003–2011.
Among the 300 SHCS participants who died, 20 (6%) died from
a cardiovascular event. Swiss HIV Cohort Study participants
had a median of 9 follow-up visits, whereas CoLaus participants
had only 1 follow-up visit. Therefore, we cannot exclude a dif-
ferential recall bias. Finally, the multivariable analyses were ad-
justed for a small number of shared variables only, and therefore
residual confounding cannot be excluded.
CONCLUSIONS
In our study, we have identiﬁed associations of HIV with in-
creased risks of hypertension and kidney and liver disease, unlike
CVD where the risk is associated with smoking. It remains to be
Figure 1. Prevalence of comorbidities derived from logistic regression
analyses adjusted for age, sex, body mass index, and smoking as an inter-
action term among 3230 Swiss HIV Cohort Study (SHCS) and 4569 Cohorte
Lausannoise (CoLaus) participants. Nonsmoking participants of CoLaus
formed the reference group. Abbreviation: CI, conﬁdence interval.
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Table 3. Numbers of Incident Comorbidities, Stratiﬁed by Cohorta
Comorbidities Among Cohort
Participants
Hypertension IR
(95% CI)
Liver Disease IR
(95% CI)
Diabetes Mellitus IR
(95% CI)
Kidney Disease IR
(95% CI)
Cardiovasc. Disease IR
(95% CI)
Stroke IR
(95% CI)
Multimorbidity IR
(95% CI)
CoLaus nonsmoking 26 (22–30) 15 (13–18) 8.5 (6.8–11) 8.2 (6.6–10) 3.5 (2.6–4.9) 1.4 (0.81–2.3) 23 (20–26)
CoLaus smoking 31 (28–35) 13 (11–15) 13 (11–15) 9.0 (7.5–11) 7.0 (5.7–8.4) 1.9 (1.4–2.8) 32 (29–35)
SHCS nonsmoking 49 (42–56) 29 (25–34) 6.0 (4.3–8.3) 13 (10–16) 2.6 (1.6–4.3) 1.1 (0.54–2.4) 30 (26–35)
SHCS smoking 47 (41–52) 26 (23–30) 5.6 (4.3–7.1) 11 (8.8–13) 5.2 (4.0–6.7) 2.0 (1.3–3.0) 38 (25–31)
Unadjusted poisson regression IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
CoLaus nonsmoking 1 1 1 1 1 1 1
CoLaus smoking 1.2 (0.98–1.4) 0.84 (0.67–1.1) 1.5 (1.2–2.0) 1.1 (0.82–1.4) 2.0 (1.1–2.9) 1.4 (0.75–2.7) 1.4 (1.2–1.6)
SHCS nonsmoking 1.9 (1.5–2.3) 1.9 (1.5–2.4) 0.71 (0.47–1.0) 1.5 (1.1–2.1) 0.74 (0.41–1.3) 0.82 (0.33–2.0) 1.3 (1.1–1.6)
SHCS smoking 1.8 (1.5–2.2) 1.7 (1.4–2.1) 0.66 (0.47–0.91) 1.3 (0.96–1.7) 1.5 (0.96–2.2) 1.4 (0.74–2.8) 1.2 (1.0–1.4)
Adjusted poisson regressionb IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
CoLaus nonsmokingc 1 1 1 1 1 1 1
CoLaus smoking 1.1 (0.92–1.4) 0.84 (0.67–1.1) 1.4 (1.0–1.8) 1.2 (0.89–1.6) 1.7 (1.2–2.5) 1.3 (0.71–2.6) 1.3 (1.1–1.6)
SHCS nonsmoking 1.9 (1.5–2.4) 1.9 (1.5–2.4) 0.81 (0.54–1.2) 2.8 (2.0–4.0) 0.83 (0.45–1.5) 1.1 (0.44–3.0) 1.7 (1.1–2.1)
SHCS smoking 2.0 (1.6–2.4) 1.7 (1.4–2.2) 0.93 (0.65–1.3) 2.6 (1.9–3.5) 2.0 (1.2–3.1) 2.3 (1.1–4.9) 1.9 (1.5–2.3)
Female sex 0.65 (0.56–0.76) 1.1 (0.91–1.3) 0.52 (0.41–0.67) 1.5 (1.2–1.9) 0.44 (0.31–0.61) 0.72 (0.42–1.2) 0.70 (0.55–0.88)
Age group, 50–65yd 1.7 (1.5–1.9) 0.82 (0.69–0.97) 2.1 (1.6–2.6) 3.0 (2.3–3.8) 4.61 (2.8–5.9) 5.0 (2.5–9.7) 1.8 (1.43–2.2)
Age group, +65ye 2.4 (2.0–3.0) 0.32 (0.22–0.47) 2.4 (1.8–3.3) 6.7 (5.0–8.9) 10 (6.9–16) 14 (6.6–28) 2.6 (1.9–3.5)
Normal weighte 1.1 (0.75–1.7) 1.1 (0.68–1.9) 3.4 (0.47–25) 0.68 (0.39–1.2) 1.4 (0.44–4.4) 0.56 (0.17–1.8) 1.6 (0.69–3.5)
Overweighte 1.8 (1.1–2.7) 1.6 (0.93–2.6) 10 (1.4–74) 0.82 (0.47–1.4) 1.4 (0.43–4.4) 0.58 (0.17–2.0) 2.2 (0.97–5.0)
Obesee 2.5 (1.6–4.0) 2.1 (1.2–3.6) 25 (3.4–178) 1.0 (0.55–1.8) 2.2 (0.68–7.3) 0.73 (0.20–2.7) 3.4 (1.5–7.9)
Abbreviations: CI, confidence interval; CoLaus, Cohorte Lausannoise; IR, incidence rate per 1000 person years of follow-up; IRR, incidence rate ratio; SHCS, Swiss HIV Cohort Study; y, year old.
a Unadjusted and adjusted results of poisson regression analyses with smoking as an interaction term.
b Poisson regression models were adjusted for all variables listed.
c Reference group: nonsmoking participants from CoLaus.
d Reference group: 35- to 49-year-old participants.
e Reference group: underweight participants.
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shown whether these associations with HIV are due to direct viral
or immunological mechanisms, coinfections (eg, viral hepatitis,
cytomegalovirus), or antiretroviral treatment [33]. In this respect,
cohort studies play an important role in pointing basic research to
relevant areas and provide phenotypes and biological samples.
However, it is obvious that multimorbidity is a very heterogeneous
composite endpoint with varying causes that require different ap-
proaches for prevention. In conclusion, from a clinical perspective,
our results suggest that emphasis should be given to smoking ces-
sation and lifestyle interventions. Furthermore, blood pressure
and kidney as well as liver function should be carefully monitored
among HIV patients, keeping in mind the increasing risk of drug-
drug interactions with increasing polypharmacy.
Supplementary Data
Supplementary material is available online at Open Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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